Parallax Volatility Advisers’s Myriad Genetics MYGN Stock Holding History

Parallax Volatility Advisers’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8,008	Closed	-$221K	–	3021
2021 Q4	$221K	Buy	+8,008	New	+$232K	﹤0.01%	1626
2019 Q3	–	Sell	-24,821	Closed	-$690K	–	3059
2019 Q2	$690K	Sell	24,821 -144,270	-85%	-$4.07M	﹤0.01%	1412
2019 Q1	$5.61M	Buy	+169,091	New	+$5.15M	0.01%	660
2018 Q3	–	Sell	-119	Closed	-$4K	–	3236
2018 Q2	$4K	Hold	119	–	–	﹤0.01%	1850
2018 Q1	$4K	Sell	119 -9,709	-99%	-$329K	﹤0.01%	1957
2017 Q4	$338K	Buy	+9,828	New	+$332K	﹤0.01%	1835
2015 Q4	–	Sell	-2,207	Closed	-$83K	–	3534
2015 Q3	$83K	Buy	+2,207	New	+$78.3K	﹤0.01%	2053

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Parallax Volatility Advisers's MYGN Position: Q1 2022 in Review

Parallax Volatility Advisers sold out of Myriad Genetics (MYGN) in Q1 2022, closing a stake of 8,008 shares — an estimated $221K sold.

Parallax Volatility Advisers first reported a position in MYGN in Q3 2015 and held it in 7 quarters. The position peaked at $5.61M in Q1 2019. 205 funds tracked by Wall St. Rank hold MYGN as of Q1 2022.

Parallax Volatility Advisers reported no remaining Myriad Genetics position as of Q1 2022 after selling out during the quarter.
Parallax Volatility Advisers sold 8,008 Myriad Genetics shares in Q1 2022, an estimated $221K.
Parallax Volatility Advisers first reported a position in Myriad Genetics in Q3 2015 and held it in 7 quarters.
Parallax Volatility Advisers's Myriad Genetics position peaked at $5.61M in Q1 2019.
205 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2022.

Based on Parallax Volatility Advisers's 13F filing for Q1 2022, filed 16 May 2022.